No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma

Bone Marrow Transplant. 2023 Dec;58(12):1390-1393. doi: 10.1038/s41409-023-02092-3. Epub 2023 Sep 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antigens, CD34
  • Child
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells
  • Humans
  • Neuroblastoma* / therapy
  • Peripheral Blood Stem Cell Transplantation*
  • Transplantation, Autologous

Substances

  • Antigens, CD34